CA2928368A1 - Pharmaceutical compositions comprising antibacterial agents - Google Patents

Pharmaceutical compositions comprising antibacterial agents Download PDF

Info

Publication number: CA2928368A1
Authority: CA; Canada
Prior art keywords: pharmaceutically acceptable; acceptable derivative; gram; compound; formula
Prior art date: 2013-10-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2928368A

Other languages

English (en)

French (fr)

Inventor

Sachin Bhagwat

Mahesh Vithalbhai Patel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wockhardt Ltd

Original Assignee

Wockhardt Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-30

Filing date

2014-10-22

Publication date

2015-05-07

2014-10-22 Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd

2015-05-07 Publication of CA2928368A1 publication Critical patent/CA2928368A1/en

Status Abandoned legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 59
239000003242 anti bacterial agent Substances 0.000 title description 22
150000001875 compounds Chemical class 0.000 claims abstract description 143
FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims abstract description 117
229960005256 sulbactam Drugs 0.000 claims abstract description 117
238000000034 method Methods 0.000 claims description 61
239000000203 mixture Substances 0.000 claims description 53
208000035143 Bacterial infection Diseases 0.000 claims description 31
208000022362 bacterial infectious disease Diseases 0.000 claims description 31
230000000844 anti-bacterial effect Effects 0.000 claims description 22
239000002552 dosage form Substances 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 14
150000002148 esters Chemical class 0.000 claims description 13
239000001117 sulphuric acid Substances 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
239000011734 sodium Substances 0.000 claims description 5
229910052708 sodium Inorganic materials 0.000 claims description 5
NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 claims description 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
229960000614 sulbactam sodium Drugs 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 2
241000588626 Acinetobacter baumannii Species 0.000 description 32
241000894006 Bacteria Species 0.000 description 28
208000015181 infectious disease Diseases 0.000 description 26
230000001580 bacterial effect Effects 0.000 description 21
239000004480 active ingredient Substances 0.000 description 16
230000000670 limiting effect Effects 0.000 description 12
150000003839 salts Chemical class 0.000 description 12
239000004615 ingredient Substances 0.000 description 10
108090000204 Dipeptidase 1 Proteins 0.000 description 9
102000006635 beta-lactamase Human genes 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
244000005700 microbiome Species 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 6
ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 6
229960002182 imipenem Drugs 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 6
229960004089 tigecycline Drugs 0.000 description 6
239000000243 solution Substances 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000012453 solvate Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
235000011149 sulphuric acid Nutrition 0.000 description 3
SDCRUJJVVGJQCY-RITPCOANSA-N (2S,5R)-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC[C@@H]2CN1CN2 SDCRUJJVVGJQCY-RITPCOANSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
108010078777 Colistin Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
241000589517 Pseudomonas aeruginosa Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
-1 beta-lactam compound Chemical class 0.000 description 2
125000003460 beta-lactamyl group Chemical group 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229960003346 colistin Drugs 0.000 description 2
239000007933 dermal patch Substances 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940060367 inert ingredients Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
229960002260 meropenem Drugs 0.000 description 2
229960003085 meticillin Drugs 0.000 description 2
239000002324 mouth wash Substances 0.000 description 2
229940051866 mouthwash Drugs 0.000 description 2
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
208000019206 urinary tract infection Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229940124586 β-lactam antibiotics Drugs 0.000 description 2
RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
241000589291 Acinetobacter Species 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
208000004429 Bacillary Dysentery Diseases 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
201000001178 Bacterial Pneumonia Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
241000588923 Citrobacter Species 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000002633 Febrile Neutropenia Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000036209 Intraabdominal Infections Diseases 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000283903 Ovis aries Species 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010061512 Serratia infection Diseases 0.000 description 1
206010062255 Soft tissue infection Diseases 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
206010048038 Wound infection Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
238000009635 antibiotic susceptibility testing Methods 0.000 description 1
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
229960003644 aztreonam Drugs 0.000 description 1
239000003781 beta lactamase inhibitor Substances 0.000 description 1
229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
108010071437 oxacillinase Proteins 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
238000007747 plating Methods 0.000 description 1
201000009430 pneumonic plague Diseases 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
230000001018 virulence Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
150000003952 β-lactams Chemical class 0.000 description 1
229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA2928368A 2013-10-30 2014-10-22 Pharmaceutical compositions comprising antibacterial agents Abandoned CA2928368A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN3422/MUM/2013		2013-10-30
IN3422MU2013 IN2013MU03422A (2)	2013-10-30	2014-10-22
PCT/IB2014/065523 WO2015063653A1 (en)	2013-10-30	2014-10-22	Pharmaceutical compositions comprising antibacterial agents

Publications (1)

Publication Number	Publication Date
CA2928368A1 true CA2928368A1 (en)	2015-05-07

Family

ID=52003013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2928368A Abandoned CA2928368A1 (en)	2013-10-30	2014-10-22	Pharmaceutical compositions comprising antibacterial agents

Country Status (10)

Country	Link
US (1)	US20160287571A1 (2)
EP (1)	EP3062793A1 (2)
JP (1)	JP2016535038A (2)
CN (1)	CN106163519A (2)
AU (1)	AU2014343327A1 (2)
CA (1)	CA2928368A1 (2)
IN (1)	IN2013MU03422A (2)
MX (1)	MX2016005539A (2)
RU (1)	RU2016115375A (2)
WO (1)	WO2015063653A1 (2)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016151543A1 (en) *	2015-03-25	2016-09-29	Wockhardt Limited	Pharmaceutical compositions comprising antibacterial agents
CN111417633B (zh)	2017-12-01	2022-05-06	齐鲁制药有限公司	一种β-内酰胺酶抑制剂的晶型及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101512738B1 (ko) *	2011-08-27	2015-04-17	욱크하르트 리미티드	1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도

2014
- 2014-10-22 US US15/030,607 patent/US20160287571A1/en not_active Abandoned
- 2014-10-22 IN IN3422MU2013 patent/IN2013MU03422A/en unknown
- 2014-10-22 AU AU2014343327A patent/AU2014343327A1/en not_active Abandoned
- 2014-10-22 EP EP14806075.9A patent/EP3062793A1/en not_active Withdrawn
- 2014-10-22 CA CA2928368A patent/CA2928368A1/en not_active Abandoned
- 2014-10-22 CN CN201480059506.8A patent/CN106163519A/zh active Pending
- 2014-10-22 WO PCT/IB2014/065523 patent/WO2015063653A1/en not_active Ceased
- 2014-10-22 JP JP2016526935A patent/JP2016535038A/ja active Pending
- 2014-10-22 RU RU2016115375A patent/RU2016115375A/ru not_active Application Discontinuation
- 2014-10-22 MX MX2016005539A patent/MX2016005539A/es unknown

Also Published As

Publication number	Publication date
RU2016115375A3 (2)	2018-07-18
AU2014343327A1 (en)	2016-05-12
WO2015063653A1 (en)	2015-05-07
JP2016535038A (ja)	2016-11-10
US20160287571A1 (en)	2016-10-06
MX2016005539A (es)	2016-10-03
RU2016115375A (ru)	2017-12-01
CN106163519A (zh)	2016-11-23
IN2013MU03422A (2)	2015-07-17
EP3062793A1 (en)	2016-09-07

Legal Events

Date	Code	Title	Description
2020-12-17	FZDE	Dead	Effective date: 20201022

Publication	Publication Date	Title
WO2016151543A1 (en)	2016-09-29	Pharmaceutical compositions comprising antibacterial agents
US20180243274A1 (en)	2018-08-30	Antibacterial compositions
US9789097B2 (en)	2017-10-17	Pharmaceutical compositions comprising antibacterial agents
EP3116545A1 (en)	2017-01-18	Pharmaceutical compositions comprising antibacterial agents
EP3107539A1 (en)	2016-12-28	Pharmaceutical combinations comprising antibacterial agents
US9827235B2 (en)	2017-11-28	Pharmaceutical compositions comprising antibacterial agents
EP3062793A1 (en)	2016-09-07	Pharmaceutical compositions comprising antibacterial agents
AU2014338612A1 (en)	2016-05-12	Pharmaceutical compositions comprising antibacterial agents
WO2015159167A1 (en)	2015-10-22	Pharmaceutical compositions comprising antibacterial agents
EP3125887A1 (en)	2017-02-08	Pharmaceutical compositions comprising cefepime or sulbactam
WO2015159263A1 (en)	2015-10-22	Pharmaceutical compositions comprising antibacterial agents
WO2018193368A1 (en)	2018-10-25	Antibacterial compositions
EP3217979A1 (en)	2017-09-20	Pharmaceutical compositions comprising antibacterial agents
WO2015059629A1 (en)	2015-04-30	Pharmaceutical compositions comprising sulbactam and imipenem